HC Wainwright & Co. Reiterates Buy on Climb Bio, Maintains $20 Price Target
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Climb Bio (NASDAQ:CLYM) with a Buy and maintains $20 price target.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Climb Bio (NASDAQ:CLYM) with a Buy and maintains $20 price target.